賽升藥業(300485.SZ):子公司君元藥業通過藥品GMP現場符合性檢查
格隆匯3月29日丨賽升藥業(300485.SZ)公佈,近日,公司接到子公司瀋陽君元藥業有限公司(簡稱“君元藥業”)藥品GMP符合性檢查結果(編號:遼22010008號)的通知。檢查範圍:顆粒劑、片劑、硬膠囊劑、丸劑(水丸)、中藥前處理及提取車間;檢查時間:2022年2月28日至2022年3月3日。
君元藥業該次通過藥品GMP現場符合性檢查,表明君元藥業四個劑型生產線、中藥前處理及提取車間符合GMP要求。相關劑型產品可投入生產,有利於完善公司產品結構,提升生產能力,擴大產品市場管線,對公司未來穩健發展有着積極的推動作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.